NCT00093080已完成2 期
A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 216
- 主要终点
- Number of participants with Clinical Benefit Response (CBR) Using Response Criteria in Solid Tumors (RECIST)
研究概览
简要总结
The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥15 years of age with metastatic and/or unresectable sarcomas of the following histological subgroups: Bone sarcomas, such as osteosarcoma and Ewings sarcoma; Leiomyosarcoma; Liposarcomas; Any other soft tissue sarcoma except gastrointestinal stromal tumors (GIST). Patients with well-differentiated liposarcoma or desmoid tumors must have demonstrated progressive disease within the previous 6 months
- •Presence of at least one measurable lesion that: Can be accurately measured in at least one dimension with longest diameter ≥20 mm using conventional techniques or ≥10 mm with spiral computerized tomography (CT) scan (or otherwise at least twice the reconstruction interval for CT or magnetic resonance imaging [MRI] scans)
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤1
- •Minimum life expectancy of 3 months
- •Adequate renal and hepatic function, as specified in the protocol
- •Adequate bone marrow function, as specified in the protocol
- •Serum cholesterol <350 mg/dL and triglycerides < 400 mg/dL
- •Male and female patients who are not surgically sterile or postmenopausal must agree to use reliable methods of birth control for the duration of the study until 30 days after the last dose of study drug
- •Able to understand and give written informed consent
排除标准
- •Women who are pregnant or lactating
- •Presence of brain metastases
- •Prior therapy with rapamycin, rapamycin analogues or tacrolimus
- •Prior anticancer treatment (chemotherapy, radiotherapy, hormonal, immunotherapy, biological response modifiers, signal transduction inhibitors, etc) within 4 weeks prior to the first dose of ridaforolimus
- •Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of ≤ grade 1 by National Cancer Institute (NCI) toxicity criteria)
- •Another primary malignancy within the past three years (except for non-melanoma skin cancer and cervical carcinoma in situ)
- •Known or suspected hypersensitivity to drugs formulated with polysorbate 80 (Tween) or any other excipient contained in the study drug
- •Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin)
- •Significant uncontrolled cardiovascular disease
- •Active infection requiring systemic therapy
- •Known human immunodeficiency virus (HIV) infection
- •Treatment with any investigational agent within 4 weeks prior to the first dose of ridaforolimus
- •Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for 2 weeks prior to first planned dose of study drug
- •Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of ridaforolimus
- •Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug
研究组 & 干预措施
Ridaforolimus
Experimental
12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
干预措施: ridaforolimus (Drug)
结局指标
主要结局
Number of participants with Clinical Benefit Response (CBR) Using Response Criteria in Solid Tumors (RECIST)
时间窗: Day 1 up to 4 years or discontinuation from study
次要结局
- Overall Survival(Day 1 to the date of death, or the date of last contact (up to 4 years))
- Duration of Response(Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years))
- Progression Free Survival(Day 1 to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years))
- Number of participants experiencing adverse events(From first dose up to 30 days after last dose (up to 1 year))
- Mean ridaforolimus blood levels within 5 minutes post intravenous infusion(Day 1 and Day 5 of Cycle 1)
- Time to Tumor Progression(Day 1 up to the first observation of disease progression, death, or the date of the last evaluation of response (up to 4 years))
- Number of participants who discontinued study drug due to adverse events(From first dose up to the last dose (up to 1 year))
研究者
相似试验
已完成
2 期
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)Hematologic MalignanciesMyelodysplastic SyndromesMyeloid MetaplasiaLymphomaLeukemiaNCT00086125Merck Sharp & Dohme LLC57
进行中（未招募）
1 期
A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinomaAdvanced endometrial carcinomaMedDRA version: 12.1 Level: LLT Classification code 10014743 Term: Endometrial carcinomaEUCTR2008-000634-53-FRARIAD Pharmaceuticals, Inc.150
进行中（未招募）
1 期
A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma - Effect of ridaforolimus in Endometrial Carcinoma Version 1.3EUCTR2008-000634-53-GBMerck Sharp & Dohme Corp.,150
进行中（未招募）
1 期
A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced SarcomaMetastatic and/or unresectable soft tissue or bone sarcoma (excluding GIST).EUCTR2004-002231-92-BEARIAD Pharmaceuticals, Inc.176
进行中（未招募）
不适用
A Phase II Study of AP23573, a mTOR Inhibitor, in Female Adult Patients with Recurrent or Persistent Endometrial CancerEUCTR2004-005094-29-ITARIAD PHARMACEUTICALS,INC.44